Circulating phthalates during critical illness in children are associated with long-term attention deficit: a study

S Verstraete1, I Vanhorebeek1, A Covaci2

  • 1Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.

Intensive Care Medicine
|December 16, 2015
PubMed

Insights

Pediatric intensive care unit (PICU) patients exposed to di(2-ethylhexyl)phthalate (DEHP) metabolites from medical devices showed long-term attention deficits. This phthalate exposure explained half of the attention deficit in children 4 years after critical illness.

Area of Science:

  • Environmental Health
  • Pediatric Critical Care
  • Neurodevelopmental Disorders

Background:

  • Environmental phthalate exposure is linked to childhood attention deficits.
  • Children in the pediatric intensive care unit (PICU) are exposed to phthalates from medical devices.
  • The long-term neurocognitive effects of this exposure in critically ill children are not well understood.

Purpose of the Study:

  • To investigate if circulating phthalates, specifically di(2-ethylhexyl)phthalate (DEHP) metabolites, leaching from medical devices contribute to long-term attention deficits in children treated in the PICU.
  • To identify exposure thresholds associated with adverse neurocognitive outcomes.

Main Methods:

  • Quantified plasma concentrations of DEHP metabolites in healthy children and children treated in the PICU.
  • Neurocognitive testing was performed 4 years after PICU treatment.
  • Multivariable bootstrap analysis identified exposure thresholds in a development cohort and validated findings in a second cohort.

Main Results:

  • Plasma DEHP metabolite concentrations were significantly higher in critically ill children upon PICU admission and remained elevated until discharge compared to healthy children.
  • Exceeding harmful DEHP metabolite exposure thresholds was independently associated with attention deficit and impaired motor coordination, even after adjusting for baseline risk factors and PICU treatments.
  • The association with attention deficit was confirmed in a validation cohort, with phthalate exposure explaining half of the observed attention deficit.

Conclusions:

  • Iatrogenic exposure to DEHP metabolites during intensive care is independently and robustly associated with significant attention deficits in children 4 years post-critical illness.
  • Findings highlight a potential environmental contributor to neurodevelopmental issues in post-PICU patients.
  • Clinicaltrials.gov identifier: NCT00214916.
Abstract

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.3K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
462
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
704
Types of Toxins01:36

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
4.0K
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
133